4,682 Shares in Celcuity, Inc. $CELC Bought by Inscription Capital LLC

Inscription Capital LLC purchased a new stake in Celcuity, Inc. (NASDAQ:CELC) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 4,682 shares of the company’s stock, valued at approximately $231,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. AlphaQuest LLC boosted its position in shares of Celcuity by 176.3% during the 2nd quarter. AlphaQuest LLC now owns 7,087 shares of the company’s stock valued at $95,000 after acquiring an additional 4,522 shares in the last quarter. Corton Capital Inc. acquired a new stake in Celcuity during the second quarter valued at approximately $175,000. Creative Planning bought a new stake in shares of Celcuity in the 2nd quarter valued at approximately $177,000. Intech Investment Management LLC raised its holdings in shares of Celcuity by 5.2% in the 2nd quarter. Intech Investment Management LLC now owns 14,855 shares of the company’s stock worth $198,000 after buying an additional 734 shares in the last quarter. Finally, Rhumbline Advisers lifted its position in shares of Celcuity by 1.2% during the 2nd quarter. Rhumbline Advisers now owns 42,697 shares of the company’s stock worth $570,000 after buying an additional 503 shares during the period. 63.33% of the stock is owned by institutional investors.

Celcuity Stock Down 0.6%

Shares of NASDAQ CELC opened at $110.13 on Friday. The company has a quick ratio of 12.26, a current ratio of 12.26 and a debt-to-equity ratio of 2.74. The company has a market cap of $5.10 billion, a price-to-earnings ratio of -30.01 and a beta of 0.25. Celcuity, Inc. has a 12-month low of $7.57 and a 12-month high of $116.44. The firm’s 50-day simple moving average is $102.29 and its 200 day simple moving average is $68.27.

Celcuity (NASDAQ:CELC) last announced its earnings results on Wednesday, November 12th. The company reported ($0.92) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.13. On average, research analysts expect that Celcuity, Inc. will post -2.62 earnings per share for the current fiscal year.

Insider Transactions at Celcuity

In other Celcuity news, Director Richard E. Buller sold 3,900 shares of the stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $96.73, for a total value of $377,247.00. Following the transaction, the director directly owned 7,260 shares in the company, valued at approximately $702,259.80. This trade represents a 34.95% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 15.77% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Needham & Company LLC set a $95.00 price target on Celcuity in a research report on Monday, October 20th. HC Wainwright reaffirmed a “neutral” rating and issued a $94.00 target price (up previously from $77.00) on shares of Celcuity in a report on Monday, November 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Celcuity in a research report on Wednesday. Wells Fargo & Company began coverage on shares of Celcuity in a research report on Friday, December 12th. They issued an “overweight” rating and a $126.00 price target on the stock. Finally, Wolfe Research started coverage on shares of Celcuity in a research note on Tuesday, November 18th. They set an “outperform” rating and a $110.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Celcuity currently has an average rating of “Moderate Buy” and a consensus price target of $105.25.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.